studying
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i believe Louie thinks that the "$10.00" is a price target when in reality it is how much the report costs.
that was a very interesting close. Would not be suprised if this takes off in the morning after that flurry of eod buys.
Very nice consolidation the past several days. Like the overall trend and the article link by RonP. Could be a great long term investment. Adding tommorow!!
that would be ridiculously awesome.
Looking strong this morning. Seems like the next leg up!
blurb from Zacks press release
Bull of the Day:
We are upgrading our rating on shares of Alexza Pharmaceuticals (Nasdaq: ALXA) to Outperform and raising our price target to $3 per share. We believe the company is on track to re-file the new drug application (NDA) on AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder by the end of July 2011.
Based on our analysis of the complete response letter (CRL) received on October 8, 2010, and our numerous conversations with management, we believe Alexza is adequately prepared to file a full response with an excellent chance to receive approval in January 2012.
We see multiple catalysts in 2011, including the NDA filing, an FDA panel review, and a potential deal for AZ-004 commercialization, prior to the FDA's decision in early 2012 as opportunities to drive the shares toward our target.
I got in last week after it came down into the lower 2teens. I like what is said about RAME from what I find.
RAM Energy Resources Reports 2010 Year-End Proved Reserves
Mar 15, 2011 15:03:00 (ET)
TULSA, Okla., Mar 15, 2011 (BUSINESS WIRE) -- --SEC Case PV-10 value of proved reserves is $364.2 million, up 8% vs last year despite sale of assets
--PV-10 value of proved reserves at year-end 2010 based on 36 months NYMEX strip prices is $483.8 million
RAM Energy Resources, Inc. (RAME, Trade ) announced today that estimates of the company's proved oil and natural gas reserves at December 31, 2010, calculated using SEC rules (SEC Case) totaled 24.4 million barrels of oil equivalent (BOE) with a PV-10 value of $364.2 million. In the fourth quarter 2010 RAM completed two property divestitures in conjunction with the execution of its strategic alternative initiative to reduce debt. RAM estimates that proved reserves associated with the sales aggregated to 4.6 million BOE and accounted for 48% of the decline in proved reserves at December 31, 2010, compared to the prior year's proved reserves of 33.9 million BOE.
In addition to the SEC Case, RAM also computed an estimate of proved reserves at December 31, 2010, using NYMEX futures strip pricing for the ensuing 36 months, the same pricing used by the company's lenders to support the company's borrowing base. RAM's borrowing base was $145 million at year-end 2010, after adjusting for property divestitures in the fourth quarter of the year. Proved reserve volumes assessed using strip pricing at December 31, 2010, which averaged $93.47 per barrel of oil and $5.03 per Mcf of natural gas, were 25.3 million BOE with a PV-10 value of $483.8 million.
The company added 545 thousand BOE of reserves during the year, replacing 25% of 2010 production of 2.2 million BOE. These results are below RAM's recent norm and reflect weather interruptions early in the year, the limited availability of crews and equipment to fracture and stimulate wells drilled in South Texas, both of which reduced planned drilling activity, and RAM's initiation of a review of strategic alternatives in mid-2010, which effectively reprioritized its capital spending and activity goals for the second half of the year. RAM continues to employ, as it has in the past, an independent petroleum engineering firm to prepare estimates of its proved reserves in all of its operating areas.
Reserve Composition
Year-end 2010 estimated proved reserves of 24.4 million BOE are composed of 13.1 million barrels of oil, 2.4 million barrels of natural gas liquids (NGLs) and 53.6 Bcf of natural gas. Crude oil and NGLs represent 64% of total proved reserves, and natural gas reserves represent the remaining 36 % of reserves. Proved developed reserves accounted for 62% of total proved reserves and accounted for 71% of the total PV-10 value of $364.2 million, providing an underpinning to the confidence in the cash flow stream in 2011 and beyond.
Forward-Looking Statements
This release includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release, other than statements of historical facts, that address estimates of reserves, including prior year reserves, alternative reserve calculations, the reconciliation of reserve quantities, estimates of PV-10, prices of oil and gas and events or developments that the company expects or believes are forward-looking statements. Although RAM believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include oil and gas prices, developmental, exploitation and exploration successes, actions taken and to be taken by governments as a result of political and economic conditions or other factors, inflation rates, continued availability of capital and financing, and general economic, market or business conditions as well as other risk factors described from time to time in the company's filings with the SEC. The company assumes no obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise.
TULSA, Okla., Mar 15, 2011 (BUSINESS WIRE) -- RAM Energy Resources, Inc. (RAME, Trade ) today announced that it will hold a conference call to review fourth quarter and full year 2010 results on March 16, 2011 at 10:00 a.m. Central Daylight Time. RAM plans to issue an earnings press release prior to the market opening on March 16, 2011. The full text of the release will be available on the company's website at www.ramenergy.com .
Like QBC. Maybe a good entry at the 50dma of .93? RAME is sick btw.
I like your board here btw. I hope to contribute some goodies myself. Cheers
could be a very nice cup and handle in the works?
RAME double bottom in with golden cross coming soon? plenty of explosion room with macd and rsi.
Protalix will request a meeting with the FDA as soon as possible to clarify the path to regulatory approval.
I just found it odd as normally 300 shares AH usually only upticks 1-2 cents.
PLX AH $10 up .52 on 300 shares. Anyone else see this?
Very imformative video. Thanks Clay Trader.
Depo $10.04 ;0)
1 min intraday, macd just curled up and ready to cross back over. Lots of room to climb. IMO
1 min intraday chart is almost oversold now. Next leg up could really go bonkers.
BOOM $10
Depo (9.70) is on fire! $10+ today is looking like a sure thing!
seeking alpha analysis of Depo by Jason Napodano
http://seekingalpha.com/article/249793-drug-approval-sales-forecast-lift-depomed-price
your link goes to "post new message" page of ihub.
Here is the link to the article
http://seekingalpha.com/article/249336-sales-potential-and-chances-of-fda-approval-for-depomed-s-dm-1796?source=yahoo
Very nice read about Depo and ABT. Has very valid points and observations.
http://seekingalpha.com/article/247836-despite-abbott-pullback-depomed-still-a-value
institutional? from their website---->
"Cantor’s Domestic Equities desk operates in the NYSE listed and Nasdaq Over-the-Counter markets, trading $60 billion worth of securities worldwide. We provide institutional clients with a unique platform for trading blocks of stocks in a variety of market conditions.
Our strength is fueled by one of the largest third market institutional sales and trading forces on Wall Street – more than 300 professionals worldwide – that is driven to deliver superior service to our extensive client base.
The unique relationships built by our large network of professionals means that you reap the benefits of efficient matching, in-depth market knowledge, strong links to clearing houses and low execution costs. Furthermore, our global presence gives us access to an attractive client base, further maximizing overall exposure and increasing liquidity.
For more information on Domestic Equities, please contact equities@cantor.com"
Santarus and Depomed Announce Availability of GLUMETZA 500 mg Tablets
Depomed (MM) (NASDAQ:DEPO)
Intraday Stock Chart
Today : Thursday 6 January 2011
Santarus, Inc. (NASDAQ: SNTS) and Depomed, Inc. (NASDAQ: DEPO) today announced that supply of GLUMETZA® 500 mg (metformin HCl extended release tablets) to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.
GLUMETZA 500 mg and GLUMETZA 1000 mg are promoted in the U.S. by Santarus through a promotion agreement with Depomed. GLUMETZA 1000 mg has remained available through pharmacies without supply interruption.
“We are pleased that GLUMETZA 500 mg is again fully available to patients and physicians,” said Depomed president and chief executive officer Carl A. Pelzel. “We would like to thank everyone at Depomed, Santarus and other involved parties for their hard work on the corrective actions associated with the June 2010 recall at the wholesale level that led to the supply disruption and their efforts on the resupply.”
Santarus president and chief executive officer Gerald T. Proehl said, “Our commercial organization is prepared and enthusiastic about promoting the GLUMETZA 500 mg dosage strength to physicians. GLUMETZA 500 mg plays an important role in the process of titrating new patients to the targeted optimal dose for metformin of 2000 mg daily. At the time of the supply interruption last June, GLUMETZA 500 mg comprised approximately 60 percent of GLUMETZA net sales and we expect it to be a significant contributor to Santarus’ future GLUMETZA promotion revenues.”
About GLUMETZA
GLUMETZA (metformin hydrochloride extended release tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. GLUMETZA may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults. GLUMETZA is available in 500 mg and 1000 mg tablets.
As with all metformin products, lactic acidosis due to metformin accumulation during treatment with GLUMETZA is a rare but potentially fatal occurrence.
May also occur in association with a number of pathophysiologic conditions.
The risk of lactic acidosis increases with the degree of renal dysfunction and the patient’s age, especially patients =80 years of age, and in those patients with congestive heart failure requiring pharmacologic management.
The risk of lactic acidosis while on GLUMETZA therapy may be significantly decreased by initial and regular monitoring of renal and liver function; using the minimum effective dose; withholding in the presence of any condition associated with hypoxemia, dehydration, or sepsis; avoidance in patients with hepatic disease; cautioning patients against excessive alcohol intake; temporarily discontinuing prior to any intravascular radiocontrast study or surgical procedure.
Lactic acidosis is a medical emergency requiring immediate discontinuation of GLUMETZA.
General supportive measures and prompt hemodialysis are recommended to correct the acidosis and remove the accumulated metformin.
GLUMETZA is contraindicated in patients with renal dysfunction, known hypersensitivity to metformin HCl or metabolic acidosis, including diabetic ketoacidosis. Use of concomitant medications that affect renal function or hemodynamic change may interfere with the disposition of metformin and should be used with caution.
Hypoglycemia does not occur in patients receiving GLUMETZA alone but could occur with deficient caloric intake or during concomitant use with other glucose-lowering agents or ethanol. Loss of glycemic control may occur when a stabilized patient is exposed to stress.
In clinical trials, the most common side effects with GLUMETZA monotherapy were diarrhea, nausea, dyspepsia, and upper abdominal pain. In a clinical trial of GLUMETZA combined with a sulfonylurea, the most common side effects included hypoglycemia, diarrhea, and nausea.
For additional information on the product, please access the prescribing information at www.glumetzaxr.com.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate Serada® is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, http://www.depomed.com.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, rifamycin SV MMX® for treatment of travelers' diarrhea and RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema. In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis. More information about Santarus is available on the company's website at www.santarus.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by either Santarus or Depomed that any of their respective plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' or Depomed’s businesses, including, without limitation: risks related to the promotion arrangement between Santarus and Depomed (including Santarus' ability to increase market demand and sales of GLUMETZA products; competition from other products, unexpected adverse side effects or inadequate therapeutic efficacy of GLUMETZA products; the ability of Depomed to ensure continued supply of GLUMETZA products in the U.S. market; the scope and validity of patent protection for GLUMETZA products, including the outcome and duration of the ongoing GLUMETZA patent litigation; and the potential for termination of the promotion arrangement); and other risks detailed in Santarus' and Depomed’s prior press releases and public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and neither Santarus nor Depomed undertakes any obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Acuform® and Serada® are trademarks of Depomed, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. Santarus® and ULTESA™ are trademarks of Santarus, Inc. CYCLOSET® is a registered trademark of VeroScience LLC. MMX® is a registered trademark of Cosmo Technologies Limited. RHUCIN® is a registered trademark of Pharming Group NV.
Im not saying you didnt buy shares. Im saying that if you buy them on the BID and not the ASK then they show up as sells in the list of trades. Click on full quote of KATX and then click on trades and you will see that your buys show as sells, because they are on the BID. Just explaining why pennystocktrader said there were more sells than buys.
if you have been buying on the bid then they are showing up as sells
The wash sale period for any sale at a loss consists of 61 days: the day of the sale, the 30 days before the sale and the 30 days after the sale. (These are calendar days, not trading days. Count carefully!) If you want to claim your loss as a deduction, you need to avoid purchasing the same stock during the wash sale period. For a sale on March 31, the wash sale period includes all of March and April.
good wash sale read
http://www.fairmark.com/capgain/wash/ws101.htm
There are pictures of the drill cores in the PR. Did you read the PR?
spot on
ask .055, bounce
I am not even going to claim to be an expert on this stuff, but with 1,545,250 in buys and 1,172,107 in sells today I would venture to guess that the market makers are just doing what they want with KATX. Just look at the trades in the last hour or so and it seems pretty clear to me. As long as we get good news on RR then the daily manipulations by mm's dont mean jack.